Serum homocysteine, asymmetric dimethyl arginine (ADMA) and other arginine-NO pathway metabolite levels in patients with psoriasis

Basit Öğe Kaydı
dc.contributor.authorBilgic, Ozlem
dc.contributor.authorAltinyazar, Hilmi Cevdet
dc.contributor.authorBaran, Hatice
dc.contributor.authorUnlu, Ali
dc.date.accessioned2020-03-26T19:07:03Z
dc.date.available2020-03-26T19:07:03Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractHyperhomocysteinemia, a well-known and independent risk factor for cardiovascular disease, has been related in several studies with psoriasis patients. It has been suggested that homocysteine leads to endothelial dysfunction by causing an accumulation of asymmetrical dimethyl arginine (ADMA), a potent endogenous nitric oxide (NO) synthase inhibitor of the l-arginine-NO pathway. However, limited data is available regarding the psoriasis and ADMA relationship. In this study, we aimed to investigate the serum levels of homocysteine, ADMA and other metabolites from the l-arginine-NO pathway in psoriasis patients. Forty-two patients with chronic plaque psoriasis and 48 controls were enrolled in the study. Serum homocysteine, ADMA, l-monomethyl-l-arginine (l-NMMA), symmetric dimethylarginine (SDMA) and l-arginine levels, and l-arginine/ADMA ratios of psoriasis patients and the control group were measured. The severity of psoriasis was assessed by the psoriasis area and severity index (PASI). The mean ADMA and homocysteine values were significantly higher, and citrulline and l-arginine/ADMA values were significantly lower in psoriasis patients compared to control subjects. However, there were no significant differences among the patient and control groups with respect to mean SDMA, l-NMMA and l-arginine values. PASI scores strongly correlated with the ADMA level and moderately correlated with l-arginine/ADMA ratio. This study suggests that the l-arginine-NO pathway metabolites, especially ADMA, may play an important role in the pathogenesis of psoriasis. Additionally, serum ADMA levels of psoriasis patients may be an indicator of the disease severity.en_US
dc.description.sponsorshipScientific Research Project Coordination Unit of Selcuk UniversitySelcuk University [13401128]en_US
dc.description.sponsorshipThis study was supported by a grant from the Scientific Research Project Coordination Unit of Selcuk University (Project No: 13401128).en_US
dc.identifier.doi10.1007/s00403-015-1553-3en_US
dc.identifier.endpage444en_US
dc.identifier.issn0340-3696en_US
dc.identifier.issn1432-069Xen_US
dc.identifier.issue5en_US
dc.identifier.pmid25708188en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage439en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s00403-015-1553-3
dc.identifier.urihttps://hdl.handle.net/20.500.12395/32540
dc.identifier.volume307en_US
dc.identifier.wosWOS:000356384200007en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofARCHIVES OF DERMATOLOGICAL RESEARCHen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectHomocysteineen_US
dc.subjectADMAen_US
dc.subjectArginine-NO pathway metabolite levelsen_US
dc.subjectPsoriasisen_US
dc.titleSerum homocysteine, asymmetric dimethyl arginine (ADMA) and other arginine-NO pathway metabolite levels in patients with psoriasisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu